NasdaqGS:IONSBiotechs
Is Ionis Pharmaceuticals (IONS) Undervalued Following Its Pullback?
Ionis Pharmaceuticals (IONS) drew investor attention after its latest share price of US$57.24, with recent returns mixed over the past month and past 3 months as traders reassessed the RNA focused biotech story.
See our latest analysis for Ionis Pharmaceuticals.
The recent 1 month share price return of 5.24% comes after a 3 month share price decline of 21.07%, while the 1 year total shareholder return of 30.74% shows that Ionis Pharmaceuticals has rewarded patient holders even as shorter term...